SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC14D9C - Written communication relating to third party tender offer:
SEC Accession No. 0001193125-22-191700
Filing Date
2022-07-12
Accepted
2022-07-12 06:09:52
Documents
6

Document Format Files

Seq Description Document Type Size
1 SC14D9C d377024dsc14d9c.htm SC14D9C 41162
2 EX-2.1 d377024dex21.htm EX-2.1 442477
3 EX-10.1 d377024dex101.htm EX-10.1 59745
4 EX-99.1 d377024dex991.htm EX-99.1 20324
5 GRAPHIC g378167g0711100751259.jpg GRAPHIC 4229
6 GRAPHIC g378167g0711100751634.jpg GRAPHIC 2963
  Complete submission text file 0001193125-22-191700.txt   575499
Mailing Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451
Business Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451 617-715-3600
LA JOLLA PHARMACEUTICAL CO (Filed by) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC14D9C
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451
Business Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451 617-715-3600
LA JOLLA PHARMACEUTICAL CO (Subject) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC14D9C | Act: 34 | File No.: 005-44849 | Film No.: 221078150
SIC: 2836 Biological Products, (No Diagnostic Substances)